Neurogene Inc.
NGNENASDAQHealthcareBiotechnology
As of Oct 22, 2026 close
- Market cap
- $547.56M
- P/E (TTM)
- -
- Forward P/E
- -
- Dividend yield
- -
- 52-week range
- $15.93$43.66
- Volume (live)
- -
- Avg. volume (3M)
- 366.54K
Neurogene (NGNE) Stock Price & Financial Analysis
Neurogene Stock Price Chart
Loading chart...
Financial Metrics & Key Statistics
Fundamental metrics, valuation ratios, and profitability indicators
| Day's Range | $24.09 - $26.38 |
|---|---|
| 52-Week High | $43.66 |
| 52-Week Low | $15.93 |
| Open | $25.74 |
| Volume (last close) | 212.37K |
| Average Volume (3M) | 366.54K |
| 50-Day MA | $32.40 |
|---|---|
| 200-Day MA | $27.49 |
| 1-Year Change | −15.43% |
| Market Cap | 547.56M |
|---|---|
| Shares Outstanding | 22.55M |
| Price to Book (P/B) | 2.52 |
| EV/EBITDA | -4.11 |
| Annual Dividend | $0.00 |
|---|---|
| Dividend Yield | 0.00% |
Source: Market prices and company fundamentals. Data as of Oct 22, 2026. Data sources and methodology
Neurogene at a Glance
As of the Oct 22, 2026 close, Neurogene (NGNE) has a market capitalization of $547.56M. Revenue fell 100.0% year over year.
As of its latest reported balance sheet, it holds $112.48M in cash and securities against $8.75M of debt, a net cash position of $103.73M.
Neurogene does not currently pay a dividend.
The share price is down 15.4% over the past year. At $24.28 (the Oct 22, 2026 close) it sits within its 52-week range of $15.93 to $43.66, below its 200-day moving average of $27.49.
Based on 8 professional analyst ratings from the past 90 days, the consensus is Buy with an average price target of $80.17, 230.2% above the Oct 22, 2026 close.
Frequently Asked Questions About Neurogene
What is the current stock price for NGNE?
As of the Oct 22, 2026 close, NGNE stock trades at $24.28. The 52-week range is $15.93–$43.66, with a day range of $24.09–$26.38.
What is the P/E ratio for NGNE?
The P/E ratio (Price-to-Earnings) for NGNE is shown in the Key Statistics section. This valuation metric helps compare Neurogene Inc. to industry peers.
Does NGNE pay dividends?
Neurogene does not currently pay a regular dividend. It reported a net loss over the trailing twelve months, so it has no earnings to distribute. Check the Dividends tab for historical dividend information.
What do analysts recommend for NGNE?
Based on ratings from 8 professional analysts over the last 90 days, the consensus for NGNE is Buy. The average 12-month price target is $80.17, a 230.2% upside from the Oct 22, 2026 close of $24.28.
What is the market cap of NGNE?
As of the Oct 22, 2026 close, Neurogene's market capitalization is $547.6M, classifying it as a small-cap company. Neurogene operates in the Healthcare sector within the Biotechnology industry.